Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Cook’s Zenith TX2 TAA Endovascular Graft achieves first placement in the USA

Cook : 25 June, 2008  (Company News)
Cook Medical has achieved the first commercial placement of its Zenith TX2 TAA Endovascular Graft in the USA.
The procedure was performed on a 69-year-old male patient by Sean Lyden, MD, a vascular surgeon and specialist in endovascular aneurysm repair (EVAR) practicing at a major medical institution in Cleveland, Ohio. Cook’s state-of-the-art aortic endograft is designed specifically to treat patients undergoing thoracic endovascular aortic repair (TEVAR) for descending thoracic aneurysms and ulcers.

“The first placement of the TX2 in the United States showcases the advanced medical technologies Cook brings to the marketplace and marks a step forward in treating a broad range of TAA patients, safely and effectively, worldwide,” said Phil Nowell, global leader of Cook Medical’s Aortic Intervention business unit. “Dr Lyden and others have told us they’ve been eagerly awaiting this device because it deploys with such accurate control and is actively fixed to the aorta, unlike competing devices. We believe this is a dramatic improvement for patients in a section of the aorta that really challenges endovascular devices for durability and that frequently offers only limited surgical repair options”.

“With the highly skilled support of vascular surgeons like Dr Lyden, we are now able to serve US patients affected by TAAs (thoracic aortic aneurysms) or ulcers with the most minimally invasive alternatives available. Cook’s TX2 can be used on an additional subset of patients who may have been ineligible for treatment through open surgery, giving those affected by the disease, the opportunity to be treated with TEVAR,” Nowell added.

“The commercial release of the TX2 really made a huge difference for this patient,” said Dr Lyden. “Using a small groin incision we were able to accomplish repair of his aneurysm in about 45 minutes. The two-piece device allowed customisation to the patient’s anatomy to sit perfectly at the level of the left subclavian artery proximally and distally to near the celiac artery and prior repair. The hydrophilic Flexor delivery system passed through his anatomy to the treatment area with remarkable ease. This device will clearly make a huge impact on treating thoracic aortic disease.”

TAAs occur when a section of the aorta weakens and bulges outward like a balloon. The Cook Zenith TX2, a reinforced fabric tube that is sized to the length of the aorta is used to seal off the aneurysm, where it helps to relieve pressure on the aneurysm or ulcer and reduce the risk of rupture. The Zenith TX2 device is deployed from a Catheter inserted through a small incision in the patient’s femoral artery.

The procedure is far less invasive than traditional open surgery where physicians open the patient’s chest, clamp off and remove the diseased section of the aorta and replace it with a surgical graft. Post-operative and post-discharge recovery times are typically shorter with TEVAR, which may help patients return to their normal lifestyle routines far faster than for those who undergo open surgery.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo